Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 11, 2008, Pages 584-590

  Maiguma, T ^a   Hayashi, Y ^b   Ueshima, S ^b   Kaji, H ^a   Egawa, T ^a   Chayama, K ^b   Morishima, T ^b   Kitamura, Y ^c   Sendo, T ^b   Gomita, Y ^a   Teshima, D ^a  

^a SHUJITSU UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cell viability; High dose methotrexate chemotherapy; Human epidermal keratinocytes; Oral mucositis; Pediatric acute lymphoblastic leukemia; Pharmacokinetic paramuters

Indexed keywords

FOLINIC ACID; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CELL VIABILITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; MALE; MUCOSA INFLAMMATION; ORAL MUCOSAL DISEASE;

EID: 56749131031     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46584     Document Type: Article

References (20)

1. Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garcia MJ. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006; 45: 1227-1238.
2. Albertioni F, Rask C, Schroeder H, Peterson C. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis. Anticancer Drugs. 1997; 8: 119-124.
3. Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther. 1978; 23: 68-72.
4. Evans WE, Crom WR, Stewart CF, Bowman WP, Chen CH, Abromowitch M, Simone JV. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet. 1984; 1: 359-362.
5. Hongo T, Okada S, Ohzeki T, Ohta H, Nishimura S, Hamamoto K, Yagi K, Misu H, Eguchi N, Suzuki N, Horibe K, Ueda K. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: A retrospective study by the JACLS. Japan Association of Childhood Leukemia Study Pediatr Int. 2002; 44: 293-299.
6. Joannon P, Oviedo I, Campbell M, Tordecilla J. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer. 2004; 43: 17-22.
7. MeGuire DB, Altamonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum. 1993; 20: 1493-1502.
8. Moe PJ, Holen A. High-dose methotrexate in childhood ALL. Pediatr Hematol Oncol. 2000; 17: 615-622.
9. Pereira Pinto L, de Souza LB, Gordon-Nunez MA, Soares RC, de Brito Costa EM, de Aquino AR, Fernandes MZ. Prevention of oral lesions in children with acute lymphoblastic leukemia. Int J Pediatr Otorhinolaryngol. 2006; 70: 1847-1851.
10. Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia-a logistic regression analysis. Acta Oncol. 1998; 37: 277-284.
11. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994; 12: 1667-1672.
12. Shimasaki N, Mori T, Samejima H, Sato R, Shimoda H, Yahagi N, Torii C, Yoshihara H, Tanigawara Y, Takahashi T, Kosaki K. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2006; 28: 64-68.
13. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998; 34: 39-43.
14. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, Le Veque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001; 19: 2201-2205.
15. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yonovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004; 16: 2590-2598.
16. Stokman MA, Spijkervet FK, Wymenga AN, Burlage FR, Timens W, Roodenburg JL, de Vries EG. Quantification of oral mucositis due to radiotherapy by determining viability and maturation of epithelial cells. J Oral Pathol Med. 2002; 31: 153-157.
17. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977; 22: 630-634.
18. Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Pediatr Blood Cancer. 2004; 43: 571-579.
19. Tung JP, Maibach HI. The practical use of methotrexate in psoriasis. Drugs. 1990; 40: 697-712.
20. Wymenga AN, van der Graaf WT, Spijkervet FL, Timens W, Timmer-Bosscha H, Sluiter WJ, de Vries EG, Mulder NH. A new in vitro assay for quantitation of chemotherapy-induced mucositis. Br J Cancer. 1997; 76: 1062-1066.